Biosimilars

 

The Benefits of Anti-TNF Biosimilars

August 18, 2020

Authors of a review say biosimilars would improve treatment, not just reduce cost.

Oncology Care Model Spurs Use of Biosimilar Filgrastim

August 17, 2020

Whether the OCM has worked out is debatable, but it has apparently encouraged the use of biosimilar versions of filgrastim.

When Will Biosimilars Start Making a Serious Difference in Oncology?

August 05, 2020

It's early days yet because patent and other issues have kept FDA-approved biosimilars off the market, but Gary Lyman, M.D., M.P.H.. of the Fred Hutchinson Cancer Research Center says there's evidence of some effect on the price of cancer supportive drugs.

Is the Biosimilars Waiting Game Finally Over?

July 30, 2020

Advocates say a number of regulatory changes could help bring more of these products on to the market.

Sandoz, Boehringer Ingelheim Battle Biosimilar Misinformation

July 24, 2020

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

Biosimilars for Cancer an 'Emerging Success' Says NCCN's Koh

July 09, 2020

Vote in May made FDA-approved biosimilars an "appropriate substitution" for brand-name biologics in NCCN guidelines.

FDA Approves Hulio, the Sixth Biosimilar to Humira

July 08, 2020

Along with the other Humira biosimilars, Hulio will not be on the market till 2023.

Biosimilars Fan Club Includes Free-Market Conservatives

July 06, 2020

Pacific Research Institute’s Winegarden Sees Dose of Competition as Way to Lower OOP Costs

Survey: Rheumatologists Still Reluctant to Switch Patients to Biosimilars

July 02, 2020

Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars. 

Challenges of Developing the Next Generation of Biosimilars

June 04, 2020

Proving therapeutic equivalence is a major hurdle.